EU Court Temporarily Suspends Ban on Ocaliva for Primary Biliary Cholangitis

The European Court of Justice in Luxembourg has granted a temporary suspension of the European Commission's decision to ban Ocaliva查看药品详情 (obeticholic acid查看药品详情), a medication prescribed for primary biliary cholangitis (搜索)搜索该疾病 (PBC (搜索)搜索该疾病). This rare liver disease progressively destroys bile ducts, potentially leading to liver failure and increasing the risk of liver cancer. The decision ensures that Ocaliva remains accessible to patients within the European Union, Iceland, Liechtenstein, and Norway, pending the outcome of a legal challenge filed by Advanz Pharma (搜索)搜索该公司, the drug's manufacturer.

EMA Recommendation and Commission's Ban

The European Medicines Agency (EMA) had recently recommended withdrawing Ocaliva查看药品详情's marketing authorization following a review by its Committee for Medicinal Products for Human Use (CHMP). The review concluded that Ocaliva did not demonstrate significant benefit over a placebo in preventing disease progression or death in early-stage PBC (搜索)搜索该疾病 patients. Consequently, the European Commission formally moved to ban the drug earlier this week.

Advanz Pharma's Response

Advanz Pharma (搜索)搜索该公司 swiftly responded by securing a temporary suspension of the ban from the EU's Court of Justice. Steffen Wagner, CEO of Advanz, stated, "We are committed to supporting patients and are pleased to have secured a temporary suspension of the EC decision. We will continue our efforts to help ensure longer-term continuity of supply of Ocaliva查看药品详情 for all patients who need it."

Concerns over Treatment Alternatives

The potential removal of Ocaliva查看药品详情 from the market had sparked protests, with patient advocacy groups arguing that there is no alternative second-line treatment licensed in Europe for PBC (搜索)搜索该疾病. Ocaliva is typically used when initial treatments, such as ursodeoxycholic acid查看药品详情, fail, stop working, or cause intolerable side effects. Advanz argues that revoking Ocaliva's authorization would leave thousands of PBC patients at increased risk of disease progression with limited treatment options.

Conditional Approval and Confirmatory Trials

Ocaliva查看药品详情 received conditional marketing authorization in both the EU and the U.S. in 2016, contingent on further studies confirming its clinical benefits. This approval was based on data from the Phase 3 POISE trial, which demonstrated Ocaliva's superiority over placebo in normalizing blood markers of liver damage. However, the subsequent Phase 3b/4 COBALT clinical trial, designed to confirm these benefits, yielded less conclusive results.

COBALT Trial Data and Real-World Evidence

Results from the COBALT trial, published last month, indicated similar rates of death, liver transplant, and/or other serious liver-related events between patients on Ocaliva查看药品详情 and placebo (28.6% vs. 28.9%). Advanz argues that the CHMP's decision focused too heavily on a single data analysis from COBALT, rather than considering real-world data gathered over seven years of clinical use. An analysis comparing COBALT participants assigned Ocaliva with an external group of untreated patients suggested a significant benefit, with a 61% lower risk of negative outcomes with Ocaliva (10.1% vs. 21.5%).

Ocaliva in the United States

In the U.S., where Ocaliva查看药品详情 is marketed by Intercept Pharmaceuticals (搜索)搜索该词条, regulators are reviewing an application for full approval. A decision is expected in October.